États-Unis · Bourse & Finance · CNBC

Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals

Publié par CNBC · États-Unis il y a 1 h

Western biopharma companies are increasingly turning to China to source innovation, as pharma's dreaded "patent cliff" draws closer.

Lire l'article complet sur CNBC Connectez-vous pour sauvegarder

MediaNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.cnbc.com)

À lire aussi

Google won a court dismissal of publishers' antitrust suits over AI search summaries

The Latest Challenge to Data Centers? Restive Investors.

BNB Chain crosses $1B in tokenized stocks, ETFs as market hits $3.7B

Cboe wants to turn VIX into a never-ending trade

US Designates Russia's A7 Network as Transnational Criminal Organization

Business Insider

Where every US governor stands on AI and the data-center boom